The latest clinical trial results from Eli Lilly show the drug manufacturer's once-weekly insulin injection is just as ...

Shortly after a positive data drop for Eli Lilly’s efsitora a | Lilly revealed that its weekly insulin candidate efsitora ...

“Obviously GLP-1, specifically the longer-acting GLP-1s, have changed the field of obesity and diabetes. And when we combine the GLP-1 and the amylin biology, there is a potential to see even ...

Clinical trials of a new, once-a-week insulin have shown that it controls blood sugar as well as daily injections of an ...

To receive the full newsletter in your inbox for free sign up here, opens new tab) Eli Lilly’s ... trial also used a short-acting insulin at mealtimes. In July, Lilly rival Novo Nordisk ...

Collaboration between giant pharmaceutical corporations and patients with very little power just doesn’t work, according to ...

Weekly insulin injections can control type 1 and type 2 diabetes just as well as daily shots, according to two new studies.

technology is now cleared for use with Eli Lilly and Company’s Lyumjev® (insulin lispro-aabc injection) ultra-rapid acting insulin in the European Union (EU). "High satisfaction and quality of ...

Weekly insulin shots can help control both Type 1 and Type 2 diabetes as well as daily injections do, a pair of clinical ...

10, 2024; Eli Lilly, news releases, Sept. 10, 2024 Once approved, a new form of insulin could allow people to receive shots once a week rather than once a day.

New research offers an alternative to daily insulin shots for the 8 million people in the United States with type 2 diabetes. Eli Lilly ... “This long-acting formulation could help address ...